carbamates has been researched along with Benign Neoplasms, Brain in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 8.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "A multicenter, retrospective case series investigation of consecutive BRAF-mutant patients with melanoma brain metastases (MBMs) treated with a combination of BRAF inhibitor encorafenib and MEK inhibitor binimetinib was conducted to evaluate the antitumor response." | 7.96 | Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. ( Amaria, RN; Amin, A; Davies, MA; Davis, JM; Diab, A; Glitza, IC; Holbrook, K; Lutzky, J; Patel, SP; Tawbi, H, 2020) |
| "Metastatic melanoma is often accompanied by the development of brain metastases, at presentation or during the course of therapy." | 5.62 | Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib. ( Hanft, S; Khullar, K; Mehnert, JM; Weiner, JP, 2021) |
| "Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone." | 5.39 | Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. ( Burlakova, N; Coicou, L; Harding-Rose, C; Holman, M; Khasabova, IA; Morse, T; Seybold, VS; Simone, DA, 2013) |
| " CDC20 expression is increased in a variety of tumors and associated with temozolomide (TMZ) resistance in glioma cells." | 4.02 | Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide. ( Ding, Y; He, L; Pan, Y; Song, X; Yu, S; Zhang, C; Zheng, C, 2021) |
| "A multicenter, retrospective case series investigation of consecutive BRAF-mutant patients with melanoma brain metastases (MBMs) treated with a combination of BRAF inhibitor encorafenib and MEK inhibitor binimetinib was conducted to evaluate the antitumor response." | 3.96 | Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. ( Amaria, RN; Amin, A; Davies, MA; Davis, JM; Diab, A; Glitza, IC; Holbrook, K; Lutzky, J; Patel, SP; Tawbi, H, 2020) |
| "Metastatic melanoma is often accompanied by the development of brain metastases, at presentation or during the course of therapy." | 1.62 | Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib. ( Hanft, S; Khullar, K; Mehnert, JM; Weiner, JP, 2021) |
| "Local injection of OMDM-1 reduced hyperalgesia in vivo in mice with unilateral tumors in and around the calcaneous bone." | 1.39 | Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain. ( Burlakova, N; Coicou, L; Harding-Rose, C; Holman, M; Khasabova, IA; Morse, T; Seybold, VS; Simone, DA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, Y | 1 |
| Zhang, C | 1 |
| He, L | 1 |
| Song, X | 1 |
| Zheng, C | 1 |
| Pan, Y | 1 |
| Yu, S | 1 |
| Holbrook, K | 1 |
| Lutzky, J | 1 |
| Davies, MA | 1 |
| Davis, JM | 1 |
| Glitza, IC | 1 |
| Amaria, RN | 1 |
| Diab, A | 1 |
| Patel, SP | 1 |
| Amin, A | 1 |
| Tawbi, H | 1 |
| McLoughlin, EM | 1 |
| Fadul, CE | 1 |
| Patel, SH | 1 |
| Hall, RD | 1 |
| Gentzler, RD | 1 |
| Li, AS | 1 |
| Leng, T | 1 |
| Nagpal, S | 1 |
| Liao, YJ | 1 |
| Khullar, K | 1 |
| Hanft, S | 1 |
| Mehnert, JM | 1 |
| Weiner, JP | 1 |
| Khasabova, IA | 1 |
| Holman, M | 1 |
| Morse, T | 1 |
| Burlakova, N | 1 |
| Coicou, L | 1 |
| Harding-Rose, C | 1 |
| Simone, DA | 1 |
| Seybold, VS | 1 |
| Winkler, K | 1 |
| Ramer, R | 1 |
| Dithmer, S | 1 |
| Ivanov, I | 1 |
| Merkord, J | 1 |
| Hinz, B | 1 |
| Dorneburg, C | 1 |
| Goß, AV | 1 |
| Fischer, M | 1 |
| Roels, F | 1 |
| Barth, TF | 1 |
| Berthold, F | 1 |
| Kappler, R | 1 |
| Oswald, F | 1 |
| Siveke, JT | 1 |
| Molenaar, JJ | 1 |
| Debatin, KM | 1 |
| Beltinger, C | 1 |
| Cenciarelli, C | 1 |
| Marei, HE | 1 |
| Zonfrillo, M | 1 |
| Casalbore, P | 1 |
| Felsani, A | 1 |
| Giannetti, S | 1 |
| Trevisi, G | 1 |
| Althani, A | 1 |
| Mangiola, A | 1 |
| Kunschner, LJ | 1 |
| Fine, H | 1 |
| Hess, K | 1 |
| Jaeckle, K | 1 |
| Kyritsis, AP | 1 |
| Yung, WK | 1 |
| Paylor, B | 1 |
| Holt, S | 1 |
| Fowler, CJ | 1 |
| Linfoot, PA | 1 |
| Gray, JW | 1 |
| Dean, PN | 1 |
| Marton, LJ | 1 |
| Deen, DF | 1 |
1 trial available for carbamates and Benign Neoplasms, Brain
| Article | Year |
|---|---|
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glio | 2002 |
11 other studies available for carbamates and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carbamates; Cell Line, Tumor; Cell Pr | 2021 |
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; | 2020 |
Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain | 2019 |
Rapid Fluctuation of Subretinal Fluid on Encorafenib and Binimetinib.
Topics: Antineoplastic Agents; Astrocytoma; Benzimidazoles; Brain Neoplasms; Carbamates; Female; Humans; MAP | 2020 |
Complete response of brainstem metastasis in BRAF-mutated melanoma without stereotactic radiosurgery after initiation of encorafenib and binimetinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Brain Neoplasms; Carbamates; F | 2021 |
Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain.
Topics: Animals; Arachidonic Acids; Benzamides; Brain Neoplasms; Cannabinoid Receptor Antagonists; Carbamate | 2013 |
Fatty acid amide hydrolase inhibitors confer anti-invasive and antimetastatic effects on lung cancer cells.
Topics: Aged; Amidohydrolases; Animals; Apoptosis; Arachidonic Acids; Benzamides; Biomarkers, Tumor; Brain N | 2016 |
γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.
Topics: Amyloid Precursor Protein Secretases; Animals; Apoptosis; Brain Neoplasms; Carbamates; Cell Cycle; C | 2016 |
The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
Topics: Apoptosis; Benzimidazoles; Brain Neoplasms; Carbamates; Cell Differentiation; Cell Proliferation; Di | 2017 |
The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH.
Topics: Amidohydrolases; Animals; Benzamides; Brain; Brain Neoplasms; Carbamates; Enzyme Inhibitors; Ethanol | 2006 |
Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate.
Topics: Alkylating Agents; Animals; Brain Neoplasms; Carbamates; Carmustine; Cell Cycle; Cell Line; Cell Sur | 1986 |